These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 15203993)

  • 1. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DC in multiple myeloma immunotherapy.
    Turtle CJ; Brown RD; Joshua DE; Hart DN
    Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DC therapy for metastatic melanoma.
    Ingram SB; O'Rourke MG
    Cytotherapy; 2004; 6(2):148-53. PubMed ID: 15203991
    [No Abstract]   [Full Text] [Related]  

  • 10. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
    Kim S; Lee JB; Lee GK; Chang J
    Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical and functional assessment of blood dendritic cells in prostate cancer patients.
    Wilkinson R; Kassianos AJ; Swindle P; Hart DN; Radford KJ
    Prostate; 2006 Feb; 66(2):180-92. PubMed ID: 16173035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vaccine therapy of prostate cancer].
    Doehn C; Böhmer T; Sommerauer M; Kausch I; Jocham D
    Aktuelle Urol; 2005 Sep; 36(5):407-16. PubMed ID: 16163603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DC-based cancer vaccines: lessons from clinical trials.
    Brody JD; Engleman EG
    Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
    [No Abstract]   [Full Text] [Related]  

  • 14. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immune response to breast cancer, and the case for DC immunotherapy.
    Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
    Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells generated from patients with androgen-independent prostate cancer are not impaired in migration and T-cell stimulation.
    Waeckerle-Men Y; Allmen EU; von Moos R; Classon BJ; Scandella E; Schmid HP; Ludewig B; Groettrup M; Gillessen S
    Prostate; 2005 Sep; 64(4):323-31. PubMed ID: 15754347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma.
    Papewalis C; Wuttke M; Jacobs B; Domberg J; Willenberg H; Baehring T; Cupisti K; Raffel A; Chao L; Fenk R; Seissler J; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Feb; 40(2):108-16. PubMed ID: 18283628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
    Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
    Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adaptive immunotherapy of the advanced prostate cancer - cancer testis antigen (CTA) as possible target antigens].
    Prikler L; Scandella E; Men Y; Engeler DS; Diener PA; Gillessen S; Ludewig B; Schmid HP
    Aktuelle Urol; 2004 Aug; 35(4):326-30. PubMed ID: 15459874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.